29 October 2024NewsPatentsRajiv Nayar President HTD Biosystems Speaker Chuck Sholtz Vice President, Intellectual Property Nutcracker Therapeutics Speaker Benjamin Pelletier Partner Haynes & Boone Moderator
WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?
The patent landscape for biologics, biosimilars, and advanced therapeutic antibodies is undergoing rapid change, presenting both opportunities and challenges for innovators and manufacturers. This panel will explore current issues and strategies in this dynamic field.
Key topics include:
Patent eligibility considerations for biologics and antibodies
The BPCIA patent dance and its implications
Navigating patent thickets in the biologics space
Strategies for prosecuting bispecific antibody patent applications around the world
Addressing novelty and non-obviousness challenges
Navigating different jurisdictional approaches
Balancing broad protection with sufficient disclosure
Strategies for overcoming rejections specific to bispecific antibodies
Comparative analysis of prosecution strategies in key markets (US, Europe, China, Japan)
Emerging trends in biologic and antibody patenting
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 February 2025 The UK’s first-ever IP compulsory mediation order resolved the football club’s trademark dispute, increasing the value of ‘problem solving’ tactics over litigation, finds Muireann Bolger.